Evidence map›Paper›PMID 27840857›Full record

ArticleAustin addiction sciences2016

Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial.

K Blum, M Febo, R D Badgaiyan

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Austin addiction sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Are We Getting High Cause the Thrill is Gone?Journal of addiction psychiatry · 2023
    Article
  8. Article
  9. Review
  10. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.International journal of environmental research and public health · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Critical Analysis of White House Anti-Drug Plan.Global journal of addiction & rehabilitation medicine · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

K BlumDepartment of Psychiatry and McKnight Brain Institute, University of Florida College of Medicine, USA; Division of Addiction Services, Dominion Diagnostics, USA; Igene, LLC, Austin, USA; Departments of Psychiatry and Behavioral Sciences, Keck School of Medicine of USC, USA; Division of Neuroscience Research and Addiction Therapy, Shores Treatment and Recovery Center, USA; Human Integrated Services Unit, University of Vermont Centre for Clinical and Translational Science, USA; Eötvös Loránd University, Institute of Psychology, Hungary; Division of Clinical Neurology, PATH Foundation NY, USA; Division of Nutrigenomics, LaVita RDS, USA.
M FeboDepartment of Psychiatry and McKnight Brain Institute, University of Florida College of Medicine, USA.
R D BadgaiyanDepartment of Psychiatry, Wright State University BoonShoft School of Medicine, USA.

Funding

Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
NINDS NIH HHS R01 NS073884
6 · The paper itself

Abstract

Dopamine along with other chemical messengers like serotonin, cannabinoids, endorphins and glutamine, play significant roles in brain reward processing. There is a devastating opiate/opioid epidemicin the United States. According to the Centers for Disease Control and Prevention (CDC), at least 127 people, young and old, are dying every day due to narcotic overdose and alarmingly heroin overdose is on the rise. The Food and Drug Administration (FDA) has approved some Medication-Assisted Treatments (MATs) for alcoholism, opiate and nicotine dependence, but nothing for psychostimulant and cannabis abuse. While these pharmaceuticals are essential for the short-term induction of "psychological extinction," in the long-term caution is necessary because their use favors blocking dopaminergic function indispensable for achieving normal satisfaction in life. The two institutions devoted to alcoholism and drug dependence (NIAAA & NIDA) realize that MATs are not optimal and continue to seek better treatment options. We review, herein, the history of the development of a glutaminergic-dopaminergic optimization complex called KB220 to provide for the possible eventual balancing of the brain reward system and the induction of "dopamine homeostasis." This complex may provide substantial clinical benefit to the victims of Reward Deficiency Syndrome (RDS) and assist in recovery from iatrogenically induced addiction to unwanted opiates/opioids and other addictive behaviors.

Indexed as

DopamineEnkephalinGlutamineKB220ZMedication Assisted Treatment (MAT)Reward Deficiency Syndrome (RDS)

Identifiers

PMID27840857
PMCPMC5103643

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.